Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABX-EGF · 5 trials · 6 indications
| Arm | Type | Description |
|---|---|---|
| ABX-EGF | EXPERIMENTAL | Open-label, single arm panitumamab monotherapy |
| Name | Type | Description |
|---|---|---|
| ABX-EGF (panitumumab) | DRUG | - |
| ABX-EGF | DRUG | 2.5 mg/kg by an infusion pump over one hour |
| paclitaxel | DRUG | - |
| carboplatin | DRUG | - |
Inclusion Criteria: * Metastatic colorectal adenocarcinoma; * Subjects must have become refractory to treatment or unable to continue treatment due to toxicity or other reasons during or after treatment with fluoropyrimidine, irinotecan and oxaliplatin for metastatic colorectal cancer including tho...
Top 20 of 77 competitors
ABX-EGF is an investigational small molecule being studied for the treatment of colorectal cancer, metastatic colorectal cancer, and non-small cell lung cancer. It is in Phase 2 clinical development and has been evaluated in completed trials for these oncology indications.
ABX-EGF is being developed by Amgen Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol AMGN. The drug is currently in Phase 2 clinical development for oncology indications.
ABX-EGF is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy in patients.
ABX-EGF has been studied in several completed Phase 2 trials, including NCT00034346, NCT00101920, NCT00111774, and NCT00327119. These trials evaluated the drug in patients with non-small cell lung cancer, colorectal cancer, and metastatic colorectal cancer.
Yes, ABX-EGF is also known as panitumumab. One clinical trial, NCT00327119, explicitly refers to ABX-EGF as panitumumab in its title, confirming that these names refer to the same investigational drug.